Postmenopausal Osteoporosis Treatment Discontinued

The Food and Drug Administration (FDA) has posted a discontinuation notice for Miacalcin Nasal Spray (calcitonin-salmon; Mylan).

Prescribing Practice Data Show Methotrexate Underutilized in RA

Methotrexate (MTX), the anchor drug in rheumatoid arthritis (RA) treatment, is currently being underutilized in the U.S., with suboptimal dosing, inadequate duration of therapy, and failure to use subcutaneous administration.

Review: Biologic Monotherapy Compared to Traditional DMARDs for RA

The analysis focused on comparing the benefits and risks of biologic monotherapy, non-TNF agents, or tofacitinib monotherapy vs. placebo or methotrexate/other DMARDs.

Benzodiazepine Users May Be at Increased Risk for Hip Fracture

Benzodiazepines and related drugs were found to increase the risk of hip fracture in patients with Alzheimer's disease.

Treatment for Painful Foot Nerve Disorder Gets Fast Track Designation

Centrexion announced that the Food and Drug Administration (FDA) has granted Fast Track designation to CNTX-4975, a novel therapy intended to treat Morton's neuroma.

Celecoxib-Associated CVD Risk Compared to Other NSAIDs in Landmark Study

For osteoarthritis or rheumatoid arthritis patients at high risk for cardiovascular disease (CVD), celecoxib, ibuprofen and naproxen carry a similar CVD risk, according to newly released results from the PRECISION trial.

Does Fracture Risk Go Up After Stopping Hormone Therapy?

For women who are former hormone therapy users, risk of fracture is not increased after discontinuing therapy, according to a study published in the The Journal of Clinical Endocrinology & Metabolism.

For RA Patients, DMARDs May Protect Against Bone Loss

A new review has found disease-modifying anti-rheumatic drugs (DMARDs) to be effective in halting progressive bone loss in rheumatoid arthritis (RA) patients, and suggests that they should be used early in treatment.

Spinraza Improves Motor Function in Spinal Muscular Atrophy Study

Biogen and Ionis have announced positive results from the Phase 3 study of Spinraza (nusinersen), an investigational treatment for spinal muscular atrophy (SMA) in children.

Review Looks at Effective Treatments for Gout Management

A treatment review for acute gout attacks and management has found strong evidence that colchicine, NSAIDs, and corticosteroids are effective in relieving pain in acute gout patients.

FDA to Review Treatment for Levodopa-Induced Dyskinesia

Adamas announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, to potentially treat levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

New DMD Drug Candidate Designated Orphan Drug

Solid Biosciences and Solid GT announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for SGT-001 for the treatment of patients with Duchenne muscular dystrophy (DMD).

Treatment for Rare Genetic Myopathy Gets Fast Track Designation

ATyr Pharma has announced that Resolaris, an investigational treatment for facioscapulohumeral muscular dystrophy (FSHD), has been granted Fast Track status by the Food and Drug Administration (FDA).

Biosimilar Inflectra Now Available

Pfizer announced that Inflectra (infliximab-dyyb) for injection will be shipped to wholesalers in late November 2016.

Heavy Cannabis Use Tied to Decreased Bone Density

Heavy cannabis smokers have lesser bone density than cigarette smokers and are prone to more fractures. That's according to a new analysis of 170 regular cannabis smokers and 114 controls who only smoke cigarettes.

Actemra Designated Breakthrough Therapy for Giant Cell Arteritis

Giant cell arteritis is a chronic, potentially life-threatening autoimmune condition that is more likely to affect women than men.

Antihypertensive Class Linked to Reduced Joint Pain, Opioid Use in Osteoarthritis

Recent evidence suggests that beta-blockers may have anti-nociceptive properties.

FDA: Osteoporosis Treatment No Longer Available

The Food and Drug Administration (FDA) has posted a discontinuation notice for Fortical (calcitonin-salmon [rDNA origin]; Upsher-Smith) Nasal Spray effective September 30, 2016.

New Oral Treatment for Uncontrolled Gout Available

Zurampic is now available for combination use with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.

NDA Submitted for Spinal Muscular Atrophy Treatment

Biogen and Ionis have completed the rolling submission of a New Drug Application (NDA) to the FDA for the approval of nusinersen, an invesigational treatment for spinal muscular atrophy (SMA), for which there is currently no approved treatment.

Duchenne Muscular Dystrophy Drug Granted Fast Track Status

Summit Therapeutics announced it has received a Fast Track designation from the Food and Drug Administration (FDA) for Ezutromid in the treatment of Duchenne muscular dystrophy (DMD).

Stelara Approved to Treat Crohn's Disease

Janssen Biotech announced that the Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohn's disease in adult patients.

FDA Approves Fourth Biosimilar Drug Amjevita

The Food and Drug Administration (FDA) has approved Amjevita (adalimumab-atto; Amgen) as a biosimilar to Humira (adalimumab; AbbVie) for various inflammatory diseases.

BLA Submitted for Investigational RA Drug

Janssen Biotech announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for the approval of sirukumab for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).

AACE/ACE: New Guidelines for Postmenopausal Osteoporosis Management

The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) announced the publication of new clinical guidelines and an accompanying algorithm to help physicians and other healthcare professionals with the diagnosis, fracture risk assessment, and treatment of postmenopausal osteoporosis

Propranolol Explored as Possible Tardive Dyskinesia Treatment

A new retrospective study found evidence which suggests that the β-adrenergic blocker propranolol, may be an effective treatment for tardive dyskinesia (TD), for which there are no current approved treatments.

Antihypertensive Drug Class May Impact Fracture Risk in Older Patients

The use of angiotensin receptor blocker (ARBs) in older men with hypertension was associated with a reduced incidence of non-vertebral fracture than angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs), according to a study published in Age and Ageing.

C. Difficile/Oral Bisphosphonate Link Examined Using FDA Reporting System

Compared to other bisphosphonates, alendronate was associated with a higher number of Clostridium difficile infection (CDI) adverse drug reactions, as indicated by the Food and Drug Administration (FDA) Adverse Event Reporting System data (FAERS).

Popular Alternative Therapies Effective for Certain Pain Conditions

The pain conditions included back pain, neck pain, osteoarthritis, fibromyalgia, severe headaches and migraine.

Can Lesinurad Added to Allopurinol Lower Serum Urate in Gout Patients?

Adding lesinurad to allopurinol provided extra benefit vs. allopurinol alone in lower serum urate (sUA) levels and is an option for patients requiring additional urate-lowering, a study published in Arthritis & Rheumatology reported.

FDA Approves First Biosimilar to Enbrel

The Food and Drug Administration (FDA) has approved Erelzi (etanercept-szzs; Sandoz) injection, a biosimilar to Enbrel (etanercept; Amgen).

Glucocorticoid Inj Permanently Discontinued

The Food and Drug Administration (FDA) is informing about the permanent discontinuation of Aristospan (triamcinolone hexacetonide injectable suspension; Sandoz).

Methotrexate Monotherapy, Combo Therapy Compared for RA

Researchers from the University of Calgary found moderate to high quality evidence that triple therapy with methotrexate + sulfasalazine + hydroxycholoroquine or combining methotrexate + most biologic disease-modifying antirheumatic drug (DMARDs) or tofacitinib demonstrated similar efficacy in controlling disease activity in methotrexate-naive patients or after an inadequate response to methotrexate.

Drug Therapies Compared for Glucocorticoid-Induced Osteoporosis

Amgen announced top-line data from a primary analysis conducted in a Phase 3 study evaluating the safety and efficacy of Prolia (denosumab) vs. risedronate in patients receiving glucocorticoid treatment.

Myopathy: Another Side Effect of PPIs?

Limited research published in Annals of Pharmacotherapy suggests that use of proton pump inhibitors (PPI) is associated with myopathy-like symptoms without long-term effects after discontinuation.

Ultrasonography Assessed as Drug Guiding Modification for Arthritis

Ultrasonography can be useful for guiding modification of anti-rheumatic drugs and steroids for patients with inflammatory arthritis (IA), according to a study published online in the International Journal of Rheumatic Diseases.

Synacthen Depot Fast-Tracked for Duchenne Muscular Dystrophy

Mallinckrodt announced that the FDA has granted Fast Track designation to the Investigational New Drug (IND) application of Synacthen Depot (tetracosactide) for the treatment of Duchenne muscular dystrophy (DMD).

Use of Drugs Linked with Fracture Risk Evaluated Post-Fracture

Exposure to prescription drugs associated with fracture risk was not consistently reduced after a fragility fracture occurrence, researchers reported in a JAMA Internal Medicine article.

FDA Designates Dusquetide Orphan Drug for Life-Threatening Immune Disorder

The FDA has granted Orphan Drug designation to dusquetide (SGX942; Soligenix) for the treatment of macrophage activation syndrome (MAS), a life-threatening complication of rheumatic disease.

Experimental Drug Reduces Fracture Risk Better than Existing Therapy in Osteoporosis Study

In postmenopausal women with osteoporosis, an experimental drug appears to reduce the risk of bone fractures better than teriparatide or a placebo, according to a study published in the Journal of the American Medical Association.

Investigational Muscle Protein Designated Orphan Drug for DMD

The FDA has granted Orphan Drug designation to TVN-102 (Tivorsan), previously referred to as recombinant human Biglycan, for the treatment of Duchenne Muscular Dystrophy (DMD).

DASH Diet May Benefit Gout Patients

A study published in Arthritis & Rheumatology has found that the DASH diet reduced serum uric acid, particularly in patients with hyperuricemia.

Gout Flares With Arhalofenate Vs Allopurinol Examined in Study

Arhalofenate (800mg) is safe and significantly decreases gout flares compared to allopurinol (300mg), according to a study published online July 27 in Arthritis & Rheumatology.

Thymectomy Tied to Multiple Benefits in Myasthenia Gravis

Thymectomy improves clinical outcomes over a three-year period in patients with nonthymomatous myasthenia gravis, according to research published in the Aug. 11 issue of the New England Journal of Medicine.

FDA Grants Priority Review to Deflazacort for Duchenne Muscular Dystrophy

The FDA has accepted for filing and granted Priority Review to the New Drug Applications (NDA) of deflazacort immediate-release tablet and oral suspension formulations for the treatment of Duchenne Muscular Dystrophy (DMD).

FDA Approves Updated ONJ Warning for Prolia, Xgeva

The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen's Prolia (denosumab) and Xgeva (denosumab).

Gelsyn-3 Now Available for Knee Osteoarthritis Pain

Bioventus announced the availability of Gelsyn-3 (hyaluronic acid), an injectable indicated for pain associated with osteoarthritis of the knee.

Hand, Hip, and Knee Osteoarthritis Risks Increase in Tandem With Weight

The incidence of hand, hip, and knee osteoarthritis (OA) increases with overweight and obesity, particularly in the knee, according to a study published in Arthritis & Rheumatology.

Ustekinumab Significantly Improves Patient-Reported Outcomes in PsA

Significant improvements in patient-reported outcomes (PROs) were seen with ustekinumab vs. placebo in 3 antecedent-exposure populations of patients with psoriatic arthritis, including those with prior methotrexate and anti-tumor-necrosis factor (TNF) use, according to findings from a study published in Arthritis Care & Research.

Interchangeability of Biosimilar and Reference TNF-α Inhibitors Examined

Preliminary data from a systematic review supported the biosimilarity and interchangeability of biosimilar and reference tumor necrosis factor alpha (TNF-α) inhibitors.

Dysport Approved for Pediatric Lower Limb Spasticity

Ipsen announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Dysport (abobotulinumtoxinA) for injection for the treatment of lower limb spasticity in patients aged ≥2 years. This approval marks Dysport as the first FDA-approved botulinum toxin for this indication.

Gout Management Updates Reflect New Treatments

The European League Against Rheumatism (EULAR) have updated their recommendations on the management of gout to reflect novel treatments and evidence surrounding already established treatments.

Analysis Identifies Uveitis Risk Factors in Ankylosing Spondylitis Patients

An analysis published in Medicine identified hip-joint lesion, prevalence of peripheral arthritis, and antistreptolysin O (ASO) and circulating immune complex (CIC) levels as risk factors that may be tied to higher rates of uveitis in ankylosing spondylitis.

Study Examines Efficacy of Ultrasound-Guided Treatment for Trigger Finger

An ultrasonographically (US)-guided percutaneous treatment using a 21-gauge needle is efficacious for trigger finger, according to a study published in the August issue of Radiology.

FDA to Review Investigational Bone-Forming Monoclonal Antibody for Osteoporosis

Amgen and UCB announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for romosozumab for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

Lab-Grown Cartilage Moves Closer to Being Hip Replacement Option

Progress has been made toward developing lab-grown cartilage that could postpone or possibly eliminate the need for hip replacement surgery in younger arthritis patients, according to research published online in the Proceedings of the National Academy of Sciences.

RA Drug Available in New Autoinjector Device

Bristol-Myers Squibb announced the launch of Orencia (abatacept) ClickJect Autoinjector, a new autoinjector for adults with moderate to severe rheumatoid arthritis.

Aleve Direct Therapy Device Available OTC for Lower Back Pain

Bayer announced the launch of Aleve Direct Therapy, a drug-free, pain relief device.

Vagus Nerve Stimulation May Help Ease RA Symptoms

Electronic stimulation of the vagus nerve may help ease symptoms of rheumatoid arthritis (RA), according to a study published online in the Proceedings of the National Academy of Sciences.

Risky Whole Body Cryotherapy Growing in Popularity

The Food and Drug Administration (FDA) is warning against misleading claims about whole body cryotherapy to treat various diseases or conditions.

CDC: Arthritis Prevalence May Rise To 78.4 Million By 2040

The prevalence of arthritis and arthritis-attributable activity limitation is projected to increase in U.S. adults by 2040, according to a study published online in Arthritis & Rheumatology.

DPP-4 Inhibitors Linked to Improved Vitamin D Balance in T2DM Patients

Findings from a study published in Acta Diabetologica support that treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with better vitamin D balance in patients with type 2 diabetes.

Do TNF Inhibitors Offer CV Benefits in Psoriasis, Psoriatic Arthritis?

In a study published in Clinical Reviews in Allergy & Immunology, researchers found that tumor necrosis factor (TNF inhibitors appeared to have clinical benefits with regard to adverse cardiovascular events in psoriasis and/or psoriatic arthritis.

Study Sheds Light on Link Between Immunotherapy and Arthritis Onset

A new study has shed light on an association between immune checkpoint inhibitors (ICIs) and the onset of inflammatory arthritis and sicca syndrome.

Hypertension, Pain Combo Drug Shown Beneficial on Kidney Function

Kitov Pharmaceuticals announced new study data from the Phase 3 study for KIT-302 (amlodipine besylate/celecoxib) in the treatment of osteoarthritis pain and hypertension, suggesting beneficial effects on renal function.

Does Prior TNFi Use Affect Secukinumab Effectiveness in Psoriatic Arthritis?

Secukinumab, a human anti-IL-17A monoclonal antibody, was shown to be effective in both tumor necrosis factor inhibitor (TNFi)-naïve and TNFi-exposed psoriatic arthritis patients, however greater improvements were noted in TNFi- naïve patients.

Higher Allopurinol Dose May be Nephroprotective in Elderly

A higher allopurinol dose provided a protective effect against incident renal failure in elderly patients, according to a study published in Annals of the Rheumatic Diseases.

Tocilizumab vs. Methotrexate Compared in Newly Diagnosed RA Patients

Immediate initiation with tocilizumab with or without methotrexate was more effective than methotrexate alone for patients with newly diagnosed rheumatoid arthritis, researchers concluded in a study published in The Lancet.

FDA to Review Deflazacort for Duchenne Muscular Dystrophy

Marathon Pharmaceuticals announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for deflazacort for the treatment of patients with Duchenne Muscular Dystrophy (DMD).

Oral Baricitinib Evaluated in RA Unresponsive to Conventional DMARDs

Eli Lilly and Incyte announced positive data from the pivotal study, RA-BEYOND, evaluating baricitinib vs. placebo for the treatment of rheumatoid arthritis (RA). Study findings were presented at the Annual European Congress of Rheumatology (EULAR 2016) in London.

Carpal Tunnel Function, Dexterity Improved With Electroacupuncture

Electroacupuncture may be a beneficial treatment option for carpal tunnel syndrome, according to a study published online June 6 in CMAJ, the journal of the Canadian Medical Association.

Sirukumab Inhibits Joint Destruction, Improves RA Symptoms, Study Shows

Janssen announced positive results from the SIRROUND-D study, a pivotal Phase 3 trial evaluating subcutaneous sirukumab (CNTO 136) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).

Biologics May Improve Fatigue in Rheumatoid Arthritis

For patients with rheumatoid arthritis (RA), biological interventions of both anti-tumor necrosis factor (anti-TNF) and non-anti-TNF agents may lead to a small to moderate improvement in fatigue.

Promising Results for Xeljanz as Potential Psoriatic Arthritis Tx

Pfizer announced top-line results from the OPAL Beyond study, the second Phase 3 trial of Xeljanz (tofacitinib citrate) for the potential treatment of patients with active psoriatic arthritis (PsA).

Cannabinoids May Benefit Pain, Sleep Issues For Rheumatic Patients

Cannabinoids may have limited benefits in rheumatic conditions, with some potential benefit in terms of pain relief and effect on sleep, according to a review published in Arthritis Care & Research.

Adherence Rates for Combination Therapies in RA Compared

Veterans with rheumatoid arthritis were significantly more likely to be persistent and adherent to a tumor necrosis factor inhibitor (TNFi) plus methotrexate combination therapy than to triple therapy with non-biologic disease-modifying antirheumatic drugs (DMARDs), a study published in Arthritis Care & Research concluded.

FDA Continues Review of Controversial DMD Treatment

Sarepta announced that the Food and Drug Administration (FDA) is continuing the pending New Drug Application (NDA) review for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

Biosimilar Candidate to Remicade Under FDA Review

The FDA has accepted for review the Biologics License Application (BLA) for SB2 (Samsung Bioepis), a biosimilar candidate to Remicade (infliximab; Janssen), for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.

Risk Factors for Bisphosphonate-Associated Fractures, Osteonecrosis ID'd

Use of bisphosphonates is associated with adverse drug reactions such as atypical femoral fractures (AFs) and osteonecrosis of the jaw (ONJ).

Which Fluoroquinolone Antibiotic Carries the Greatest Risk of Tendinopathy?

Given the widespread use of fluoroquinolone antibiotics, clinicians should be aware of factors that may put patients at increased risk for tendinitis or tendon rupture, according to an article published in Pharmacotherapy.

Preventing Anemia After Orthopedic Surgery: The Role of Iron, ESA Pharmacotherapy

The use of intravenous (IV) or oral iron with or without an erythropoiesis-stimulating agent (ESA) may help prevent post-operative anemia and reduce blood transfusion without significantly raising the risk of adverse events, study authors reported in a study published in Annals of Pharmacotherapy.

FDA Grants Priority Review to Advanced Soft Tissue Sarcoma Tx

The FDA has granted Priority Review for the Biologics License Application (BLA) for olaratumab (Lilly), in combination with doxorubicin, for the potential treatment of advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.

FDA Advisory Committee Votes Against DMD Drug Approval

A majority of The Food and Drug Administration's (FDA) Advisory Committee voted against recommending eteplirsen, which in its New Drug Application (NDA), proposes to become the first drug to treat Duchenne muscular dystrophy.

Gene Variant Linked to Severe Cutaneous Reactions with Gout Treatment

Findings from a new study published in Seminars in Arthritis and Rheumatism show significant racial disparities in the risk of gout patients developing a serious, sometimes fatal adverse reaction to urate-lowering drugs.

REMS Requirement Removed for Gout Drug

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Krystexxa (pegloticase; Horizon) Injection.

New Biosimilar Inflectra Gets FDA Approval

The Food and Drug Administration (FDA) has approved Inflectra (infliximab-dyyb; Celltrion) for injection, a biosimilar to Remicade (infliximab; Janssen).

Certain ADHD Drugs May Lower Bone Density

Youth who take stimulants to treat attention deficit hyperactivity disorder (ADHD) may have a lower bone density than their peers who do not take stimulants, according to a study presented at ENDO 2016.

Certain Antidepressants May Up Bone Loss During Lactation

Selective serotonin reuptake inhibitors (SSRIs) use during pregnancy and lactation can result in decreased bone density in mothers, increasing their risk of fractures later in life, a study presented at ENDO 2016 has found.

Radius Submits NDA for New Osteoporosis Tx in Postmenopausal Women

Radius Health announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for abaloparatide-subcutaneous (SC) 80mg, a once daily treatment for postmenopausal women with osteoporosis.

Arthritis Patients May Be More Prone to Developing Periodontitis

Rheumatoid arthritis (RA) patients have a greater prevalence and severity of periodontitis than the non-arthritis population, according to a new study published in the Korean Journal of Internal Medicine.

Febuxostat vs. Allopurinol for the Prevention of Tumor Lysis Syndrome

The efficacy and safety of febuxostat was noninferior to allopurinol for preventing tumor lysis syndrome (TLS) in patients with malignant tumors about to receive chemotherapy, according to a new study published in the journal, Oncology.

Promising Results for Romosozumab in Men with Osteoporosis

Amgen and UCB announced positive top-line results from the pivotal Phase 3 study, BRIDGE, evaluating romosozumab for the treatment of osteoporosis in men.

Vaccination Recommendations for RA Patients on DMARD Therapy

Vaccination rates in patients with rheumatoid arthritis remain poor "despite the high rates of infectious disease-related morbidity and mortality," a review published in Clinical Opinion in Rheumatology has found.

Efficacy of NSAIDs Compared for Osteoarthritis Pain

Diclofenac 150mg per day was determined as the most effective non-steroidal anti-inflammatory drug (NSAID) available for improving both pain and function in patients with osteoarthritis, according to a study published in The Lancet.

Corticosteroid Injection Currently in Shortage

The FDA is reporting a shortage in certain presentations of Solu-Medrol Powder for Injection (Pfizer) and the generic Methylprednisolone sodium succinate for injection (Fresenius Kabi).

Investigational Treatment Shows Superiority in RA Study

Regeneron and Sanofi announced their Phase 3 study for sarilumab has met its primary endpoint, demonstrating superiority over adalimumab in improving symptoms in patients with active rheumatoid arthritis (RA) at Week 24, in the SARIL-RA-MONARCH trials.

Study Tests Potential Benefits of Vitamin D Supplementation in Knee Osteoarthritis

For patients with knee osteoarthritis, supplementation with vitamin D does not slow cartilage loss or alleviate knee pain.

Long-Term Safety Data for Otezla Announced

Celgene announced long-term safety data for Otezla (apremilast) from ongoing clinical trials at the American Academy of Dermatology's Annual Meeting.

Study Reveals Negative BMD Association With ADHD Meds in Adolescents

A significant difference in bone mineral density (BMD) was noted in patients aged 8-17 who have used ADHD medication, compared to their same aged counterparts who have not taken the medication.

Survey Reveals Docs Prescribing Preferences for Osteoporosis Tx

A recent online survey has found that physicians in the United States tend to prefer weekly or monthly regimens when prescribing treatment for patients with osteoporosis.